Responders to Rhythmic Auditory Stimulation in Individuals Post-Stroke and Older Adults

Sponsor
Boston University Charles River Campus (Other)
Overall Status
Recruiting
CT.gov ID
NCT06085248
Collaborator
(none)
44
1
2
5.4
8.1

Study Details

Study Description

Brief Summary

Stroke is among the leading causes of long-term disability worldwide. Post-stroke neuromotor impairments are heterogeneous, yet often result in reduced walking ability characterized by slow, asymmetric, and unstable gait patterns. Rhythmic Auditory Stimulation (RAS) is an emerging rehabilitation approach that leverages auditory-motor synchronization to retrain neuromotor control of walking. Indeed, walking with RAS can enhance walking rhythmicity, gait quality, and speed. RAS is a potentially valuable tool for walking rehabilitation after stroke; however, despite extensive research evidence on the overall benefits of RAS in people with chronic stroke, the notable variability in the walking characteristics of individual patients is likely to influence the effectiveness of RAS intervention, and thus requires study. Furthermore, beyond stroke-related factors, age-related changes may also affect how well individuals post-stroke respond to RAS. This study aims to recruit 24 individuals post-stroke and 20 older adults to evaluate the effects of stroke- and age-related neuromotor impairment on RAS intervention. Each study participant will complete two six-minute walk tests: one without RAS (baseline) and the other with RAS delivered using a metronome. The investigators hypothesize that post-stroke individuals will, on average, exhibit a positive response to RAS intervention (i.e., walk farther and with greater gait automaticity (i.e., reduced stride time variability), with the degree of response predicted by specific baseline characteristics. Furthermore, the investigators anticipate that these walking enhancements will be accompanied by improvements in gait biomechanics and a reduction in the metabolic cost of walking. The investigators hypothesize that older adults will exhibit similar, but attenuated, effects of RAS.

Condition or Disease Intervention/Treatment Phase
  • Device: Subject-specific optimized RAS
  • Behavioral: Active walking
Phase 1

Detailed Description

Stroke is among the foremost causes of long-term disability worldwide. Though post-stroke neuromotor impairments are heterogeneous, they often result in reduced walking ability and physical activity, and a slow, asymmetric, and unstable gait. In the chronic phase of stroke, the persistence of walking impairment leads to subsequent declines in walking ability, setting off a cycle of disability and deconditioning, reduced mobility, and increased fall risk. The development and study of interventions that can improve walking ability after stroke has been identified as a top priority among patients, clinicians, and researchers, with the ultimate goal being the enhancement of independence and overall quality of life, and the mitigation of walking-related disability.

Stroke is a disease of aging, and older adults (OA) tend to walk more slowly and with a more variable walking pattern that is energetically more demanding. Similar to stroke survivors, the reduced function and quality of walking in older adults can lead to declines in walking ability, initiating a cycle of disability and deconditioning that increases the risk of injurious falls. Hence, maintaining walking function is crucial for preserving a high quality of life.

Rhythmic Auditory Stimulation (RAS) is a rehabilitation intervention that has shown promise for improving walking in both stroke survivors and older adults. Walking with RAS intervention has been proven to enhance walking function, particularly in terms of walking speed. RAS relies on the innate human capacity to synchronize movements with an external rhythm, such as walking to a regular auditory beat, a process referred to as auditory-motor entrainment. Rhythmic entrainment may stabilize gait patterns and reduce the metabolic cost of walking, as the body naturally selects a walking frequency that maximizes stability and minimizes energy expenditure. Moreover, rhythmic entrainment is thought to reduce the cognitive demand of walking, allowing individuals to allocate their attention to secondary tasks essential for safe community navigation. Despite the evidence supporting its effectiveness in improving walking speed and gait function, the biomechanical changes enabling these improvements are not well understood.

Furthermore, while RAS is an effective intervention, not everyone benefits from it equally. Individuals with stroke present with a wide variety of gait patterns, and the degree of gait impairment may influence the effectiveness of RAS intervention above and beyond any age-related changes. In this study, the investigators aim to identify predictors of the response to RAS intervention. More specifically, they seek to understand the association between baseline walking characteristics and the effect that RAS intervention has on walking ability.

For this analysis, the investigators define responders in three ways: (1) individuals who experience an increase in walking function, (2) individuals who see an improvement in gait quality, or (3) individuals who achieve enhancements in both gait quality and walking function while walking with personalized RAS.

The investigators hypothesize that post-stroke individuals with particular movement characteristics will exhibit increased walking distances and greater automaticity (i.e., reduced stride time variability) in the RAS condition compared to the baseline condition. Given that RAS promotes walking automaticity, the investigators anticipate that individuals with higher walking variability will derive the greatest benefit. Furthermore, investigators hypothesize that older adults with similar movement characteristics will also demonstrate increased walking distances and improved automaticity in the RAS condition compared to the baseline condition; however, it is expected that the effect size will be smaller in comparison to stroke survivors.

The investigators hypothesize that individuals who experience immediate improvements in walking function and/or gait quality while walking with personalized RAS are more likely to respond positively to long-term RAS intervention. However, the mechanism of action enabling this long-term response is expected to differ based on baseline deficits. The short-term, immediate responses to RAS measured in this study may provide insights into potential long-term mechanisms.

Study Protocol:

To assess the varied effects of RAS intervention, each participant will undergo a data collection session involving a series of population-specific clinical tests to characterize a sample of study participants. These tests include the Timed Up and Go (Stroke-specific), Functional Gait Assessment (Stroke-specific), Mini Balance Evaluation System (Older Adults-specific), Short Physical Performance Battery (Older Adults-specific), Mini-Mental State Examination (Older Adults-specific). In addition, all study participants will complete the 10-meter walk test (10MWT) at both a comfortable and fast walking speed and the 6-minute walk test (6MWT). Additionally, the 6MWT will be fully instrumented using motion capture cameras to track retro-reflective markers, wireless inertial measurement units, and force plates embedded in the walkway. These systems will enable simultaneous collection of gait kinematic, inertial, and kinetic signals, respectively. Metabolic measures will also be recorded during the 6MWT using indirect calorimetry.

Following the baseline 6MWT, participants will wear a custom, metronome-based RAS device. This device will employ a metronome application and bone-conducting headphones to provide auditory cues tailored to each participant based on a brief tuning procedure. Subsequently, the 6MWT will be repeated with RAS set to the patient-tailored metronome frequency.

The primary objective of this study is to assess the impact of personalized RAS on walking function (measured as the total distance covered in the 6MWT) and gait quality (evaluated by stride time variability) within each population group (stroke survivors and older adults). The investigators will also analyze RAS-induced changes in secondary gait quality metrics, including (1) the metabolic cost of transport, (2) ground reaction forces during walking, (3) joint kinetics, and (4) spatial-temporal gait parameter changes induced by varying distances. A secondary objective is to determine whether RAS-induced changes in walking function and/or gait quality are linked to specific baseline walking and gait impairment patterns (i.e., movement phenotypes) and whether these movement patterns are influenced by age.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
44 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Subjects will complete a 6MWT without RAS and then complete a 6MWT with RASSubjects will complete a 6MWT without RAS and then complete a 6MWT with RAS
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Responders to Metronome-based Rhythmic Auditory Stimulation in Individuals Post-Stroke and Older Adults
Actual Study Start Date :
Sep 18, 2023
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Walking without personalized rhythmic auditory stimulation

Subjects will complete a 6MWT without any auditory cues

Behavioral: Active walking
walking without RAS cue

Experimental: Walking with personalized rhythmic auditory stimulation

Subjects will complete a 6MWT with personalized rhythmic auditory cues

Device: Subject-specific optimized RAS
Walking with metronome-based RAS cueing
Other Names:
  • RAS
  • Behavioral: Active walking
    walking without RAS cue

    Outcome Measures

    Primary Outcome Measures

    1. Six Minute Walk test distance [[RAS-Baseline]]

      difference in total distance walked with and without RAS within population. (m)

    2. Stride time variability [[RAS-Baseline]]

      difference in stride time variability with and without RAS (%) within population

    Secondary Outcome Measures

    1. Metabolic Cost of Transport [[RAS-Baseline]]

      difference in energy cost of walking with and without RAS. Metabolic cost of transport is defined as metabolic energy (measured directly from COSMED) per kg of body weight (in mL/s/kg or W/kg) divided by the average speed during the six minute walk test within population (mL/kg/m or J/kg/m).

    2. Ground Reaction Forces [[RAS-Baseline]]

      difference in Anterior Posterior GRF within population -- including both peak and impulse (%bw)

    3. speed changes over the 6MWT [[RAS-Baseline]]

      the difference in changes in walking speed over the 6MWT within population (m/s)

    4. stride length changes over the 6MWT [[RAS-Baseline]]

      the difference in changes in stride length over the 6MWT within population(cm)

    5. cadence changes over the 6MWT [[RAS-Baseline]]

      the difference in changes in cadence over the 6MWT within population (steps/min)

    Other Outcome Measures

    1. Stroke vs. older adults: Stride time Variability in responders [[RAS-Baseline]]

      difference in stride time variability with and without RAS (%) for responders across population

    2. Stroke vs. older adults: Six Minute Walk test distance in responders [[RAS-Baseline]]

      difference in total distance walked with and without RAS for responders across population

    3. spatial temporal relationships over the 6MWT: Speed to Cadence [[RAS-Baseline]]

      the difference in changes in a relationship (linear regression) between speed and cadence within population

    4. spatial temporal relationships over the 6MWT: Speed to Stride length [[RAS-Baseline]]

      the difference in changes in a relationship (linear regression) between speed and stride length within population

    5. spatial temporal relationships over the 6MWT: Cadence to Stride length [[RAS-Baseline]]

      the difference in changes in a relationship (linear regression) between cadence and stride length within population

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Be able to communicate with investigators clearly

    • The ability to walk without another individual supporting the person's body weight for at least 6 minutes. Assistive devices, such as a cane, are allowed.

    Exclusion Criteria:
    • Inability to communicate (as assessed by a licensed physical therapist)

    • Pain that impairs walking ability (as assessed by a licensed physical therapist)

    • Unexplained dizziness in the last 6 months (self-report)

    • Severe comorbidities that affect walking or may interfere with the ability to participate in the study (musculoskeletal, cardiovascular, pulmonary, and neurological)

    • More than 2 falls in the previous month

    Stroke-specific Inclusion Criteria:
    • at least 6 months post-stroke
    Older adults specific Inclusion Criteria:
    • 65 to 80 years of age

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Boston University Neuromotor Recovery Laboratory Boston Massachusetts United States 02215

    Sponsors and Collaborators

    • Boston University Charles River Campus

    Investigators

    • Principal Investigator: Louis Awad, PT, DPT, PhD, Boston University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Lou Awad, PT, DPT, PhD, Associate Professor, Boston University Charles River Campus
    ClinicalTrials.gov Identifier:
    NCT06085248
    Other Study ID Numbers:
    • 4440-SK
    First Posted:
    Oct 16, 2023
    Last Update Posted:
    Oct 16, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Lou Awad, PT, DPT, PhD, Associate Professor, Boston University Charles River Campus
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 16, 2023